Clinical trials
Low Risk Prostate Cancer clinical trials
Below are recruiting low risk prostate cancer clinical trials, each written for real people, not researchers. We’re tracking 165 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT02526797Enrolling by invitation
MRI scan study for men on active surveillance
This trial tests how a special MRI scan (with multiple measurements) may help men with low-risk prostate cancer who are monitoring it closely instead of treating right away. It may help doctors better understand the cancer’s status during active surveillance.
HerlevAges 18–75 - NCT05107674RecruitingPhase 1
Early drug study for advanced cancers that have limited options
This Phase 1 study tests NX-1607 in adults with advanced cancers that are hard to treat with standard care. It focuses on safety and early signs of how well the drug may work in specific cancer types.
Duarte, CaliforniaAges 18 years+ - NCT05308264RecruitingPhase 1/Phase 2
R289 for lower-risk MDS that still needs blood support
This Phase 1/2 study tests R289 in adults with lower-risk myelodysplastic syndromes (MDS) whose disease keeps causing anemia and/or ongoing need for red blood cell transfusions. It may help reduce blood problems and treat MDS when standard options haven’t worked well enough or aren’t suitable.
Los Angeles, CaliforniaAges 18 years+ - NCT03648359Enrolling by invitation
MRI scans to monitor low-risk prostate cancer in active surveillance
This trial uses special MRI scans to help track low-risk prostate cancer while you stay on active surveillance (meaning no immediate treatment). It may help your care team better understand changes in the cancer over time.
HerlevAges 18–75 - NCT07422480RecruitingPhase 3
Comparing elritercept to epoetin alfa for anemia in MDS needing transfusions
This trial tests a new drug called elritercept against a standard treatment, epoetin alfa, for people with a low-risk form of MDS who need regular blood transfusions for anemia. The goal is to see if elritercept works better to reduce the need for transfusions.
Gilbert, ArizonaAges 18 years+ - NCT06499285RecruitingPhase 3
Study of elritercept for anemia in low-risk MDS needing transfusions
This trial tests an investigational drug called elritercept for adults with a specific type of low-risk MDS (myelodysplastic syndromes) who have anemia (low red blood cells) and need regular blood transfusions. The goal is to see if elritercept can reduce or eliminate the need for transfusions.
Duarte, CaliforniaAges 18 years+ - NCT05810467Recruiting
Active surveillance study for men at higher risk prostate cancer
This trial studies how well “active surveillance” works for men with prostate cancer who are considered higher risk because of family history or genetics. It aims to safely monitor the cancer and decide the best timing for treatment if needed, while tracking side effects and follow-up success.
Sutton, SurreyAges 18 years+ - NCT05864196RecruitingPhase 1
Testing two-shot prostate radiation with MRI-guided planning
This early-phase study tests a prostate radiation approach given in two treatments, planned using MRI. It’s designed for men with lower-to-intermediate risk prostate cancer and aims to see if this method is safe and works well.
Mineola, New YorkAges 18 years+ - NCT06600698RecruitingPhase 1/Phase 2
Herbal supplement for rising PSA in prostate cancer
This study tests an herbal supplement called AGN-INM176 in men with prostate cancer whose PSA is rising but whose cancer has not spread. It aims to see if the supplement can safely slow PSA rise without the need for hormone therapy or other treatments.
Hershey, PennsylvaniaAges 40 years+ - NCT05043012Recruiting
Testing a special MRI scan for prostate cancer diagnosis
This study checks how well a new prostate MRI scan (using a flexible coil and multiple MRI types) can correctly identify prostate cancer and help with treatment planning. You may be able to help doctors improve prostate imaging before you have surgery.
Houston, TexasAges 18 years+ - NCT04606446RecruitingPhase 2
Study drug for ER-positive, HER2-negative cancers after treatment
This Phase 2 study tests a new Pfizer medicine (PF-07248144) for certain advanced or metastatic breast, prostate, or lung cancers that have not responded to standard treatment or no standard options exist. You may qualify if you have a specific tumor type and a limited number of prior cancer treatments, and if your body functions (blood, liver, kidneys) and heart rhythm meet safety limits.
Scottsdale, ArizonaAges 18 years+ - NCT07287917RecruitingPhase 1/Phase 2
Testing a new drug combo for advanced breast cancer or melanoma
This trial tests a new combination of drugs (AMXT 1501, DFMO, and standard therapies) for people with advanced solid tumors, specifically breast cancer (ER+ HER2-) or melanoma that has progressed after other treatments. The goal is to see if this combination can help shrink tumors or slow their growth.
Tucson, ArizonaAges 18 years+ - NCT04896801Recruiting
MRI-guided radiation for certain prostate cancer risks
This trial tests a precise, MRI-guided radiation treatment given over 7 days for people with prostate cancer in specific risk categories. It may help shrink or control the cancer while carefully targeting the tumor.
BrusselsAges 18 years+ - NCT06037980RecruitingPhase 2/Phase 3
Chemotherapy before surgery for high-risk bile duct cancer
This trial tests whether receiving chemotherapy (cisplatin, gemcitabine, and nab-paclitaxel) before surgery can improve outcomes for people with high-risk bile duct or gallbladder cancer. It compares this approach to going straight to surgery.
AnconaAges 18–75 - NCT07202247RecruitingPhase 2
Improving heart health in prostate cancer patients on hormone therapy
This study tests whether combining a time-restricted eating plan, a heart-healthy diet, and a weight-loss medication (GLP-1 receptor agonist) can help improve heart health and weight in men with prostate cancer who are receiving hormone therapy. It aims to reduce the risk of heart problems caused by hormone treatment.
Duarte, CaliforniaAges 30–79 - NCT07391982Recruiting
Short course MRI-guided radiation for prostate cancer
This trial tests a shorter radiation plan using an MRI machine to guide treatment. The goal is to see if two high-dose sessions work just as well as longer treatment, with fewer side effects. It is for men with low or intermediate risk prostate cancer.
AmsterdamAges 18 years+ - NCT06177093Recruiting
Higher dose prostate radiation with MRI guidance
This study tests a higher dose of radiation for prostate cancer using an MRI-guided machine (MR-Linac). It aims to see if a more targeted dose can be safely given to the tumor while protecting healthy tissue.
Toronto, OntarioAges 18 years+ - NCT07322263RecruitingPhase 2
Gemcitabine and docetaxel for bladder cancer that returned after BCG
This trial tests a combination of two chemotherapy drugs (gemcitabine and docetaxel) given directly into the bladder to treat high-risk non-muscle-invasive bladder cancer that has come back or not responded to BCG therapy. It's for people who cannot or choose not to have their bladder removed.
Iowa City, IowaAges 18–99 - NCT06825091RecruitingPhase 3
Comparing new SBRT to standard radiation for prostate cancer
This trial compares a newer, more precise type of radiation (adaptive SBRT) with standard image-guided radiation for prostate cancer. It aims to see if the newer approach is better at targeting the tumor while reducing side effects.
Toronto, OntarioAges 18 years+ - NCT06636123RecruitingPhase 1
Testing GZ17-6.02 for advanced prostate cancer after hormone therapy
This trial tests a new drug combination (GZ17-6.02) for men with advanced prostate cancer that has stopped responding to standard hormone therapies. The goal is to see if the drug can help slow down the cancer.
Richmond, VirginiaAges 18 years+ - NCT07259213RecruitingPhase 1/Phase 2
Study of a new drug (161Tb-RAD402) for men with advanced prostate cancer
This trial tests a new radioactive drug designed to target and destroy prostate cancer cells. It is for men whose cancer has continued to grow despite hormone therapy and other treatments like enzalutamide or abiraterone.
Wollongong, New South WalesAges 18 years+ - NCT05033301Recruiting
Nurse Ned Clinic support for prostate cancer survivors
This study tests a nurse-led clinic (“Nurse Ned Clinic”) to see how well it supports men after curative (potentially curative) prostate cancer treatment. It may help you manage follow-up care during survivorship if you are at low risk of cancer coming back.
Toronto, OntarioAges 18 years+ - NCT05558007RecruitingPhase 2
Topical treatment trial after prostate surgery in men
This Phase 2 study tests how safe and effective a topical medicine (BZ371A) is for men after prostate surgery, with the goal of improving sexual recovery and monitoring side effects. You may be able to join if you meet specific timing, health, and medication criteria after radical prostatectomy.
Belo HorizonteAges 40–65 - NCT06847867RecruitingPhase 2
Testing momelotinib for low-risk myelodysplastic syndrome
This study tests a new drug, momelotinib, for people with a low-risk form of myelodysplastic syndrome (MDS) who need red blood cell transfusions and have already tried one other treatment (like ESAs or luspatercept). The goal is to see if momelotinib can help reduce transfusion needs.
Goodyear, ArizonaAges 18 years+
Hear when a new Low Risk Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for low risk prostate cancer?
- Yes. Clin2 currently lists 165 recruiting low risk prostate cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a low risk prostate cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a low risk prostate cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.